NWBO is not publicly stating the confounding issue and many "experts" are basing their opinion of what has been represented as a clean trial with no issues. None of the TLD presentations are communicating the OS confounding issue from the crossover. But NWBO will have to notify FDA of the confounding issue in their application or it will be consider fraudulent.
Many clinicians are on NWBO's payroll and have conflicts of interest. That is always an issue with clinicians.
I'm communicating what is clearly stated (albeit buried) in NWBO's SEC filings that are clearly not being read by many on this board. They are clearly stating they have confounded naive OS data. You can question this but you are question what NWBO has filed with the SEC under oath. I'll go with what they are saying. They just aren't saying it publicly.
Market Data 
Markets 
AI
